## Figure 1

### 40% of pharma companies are including expected savings from generative artificial intelligence in their 2024 budgets

#### Percentage of executives who say that savings from generative artificial intelligence are being incorporated into 2024 budgets

|        |         |         |         |            |
|--------|---------|---------|---------|------------|
| Total  | Small   | Midsize | Large   | Big Pharma |
|        | (less than $1 billion) | ($1 billion to $10 billion) | ($10 billion to $25 billion) | (greater than $25 billion) |
| 40%    | 36%     | 44%     | 41%     | 38%        |

*Source: Bain Generative Artificial Intelligence in Pharma Survey, September 2023 (N=100)*

Nearly 60% of executives say that they have moved beyond ideation and brainstorming to building out use cases. In fact, 55% reported that they expected to have multiple proof-of-concept or minimum viable product builds by the end of 2023.

With companies large and small making significant headway in realizing the benefits of generative AI, what will separate the best from the rest? Over the